Paris, June 21, 2024. Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place June 22-26, 2024, ...

Fitusiran antithrombin-based dose regimen targeting 15%-35% of antithrombin activity demonstrated favorable safety profile in male participants aged ≥ 12 years with severe hemophilia A or B, with or ...

Two trials presented at the annual meeting of the American Society of Hematology (ASH) showed that treatment with the antithrombin inhibitor fitusiran reduced the bleeding rate in patients with severe ...

(Bloomberg) -- Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients greater ...

Paris, France - September 7, 2017 - Sanofi alliance partner Alnylam Pharmaceuticals today provided an update on the clinical development program for fitusiran, an investigational RNAi therapeutic in ...

Editor's note: This story has been updated from the previous version. The US Food and Drug Administration (FDA) has approved fitusiran (Qfitlia, Sanofi) for bleeding prophylaxis in patients aged 12 ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off on ...

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR ...

Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from ...